Telix Precision Medicine Announces AlFluor™ Radiochemistry Platform
Melbourne (Australia) and Indianapolis (U.S.) | 20 June 2025
Telix today announces it has launched a novel PET[1] radiochemistry solution based on 18F-aluminium fluoride (AlF), named AlFluor™.
The AlFluor™ platform technology enables flexible radiolabeling of PSMA[2] with either AlF or gallium-68 (68Ga). It also has the potential to be used with ligands targeting NETs[3] and FAP[4], as well as other novel imaging agents under development by Telix and its strategic partners. Developed to combine the imaging benefits of 18F with the convenience of 68Ga kit-based workflows, the AlFluor™ platform supports both centralized cyclotron manufacturing and distributed “shake-and-inject” kit production. This flexibility allows a complementary product with the same targeting agent to be labeled with either isotope, catering to clinical setting or physician preference.
As part of AlFluor’s development, Telix has signed a strategic agreement with University Hospital Ghent and Ghent University for a novel [18F]AlF-PSMA-11 targeting agent. The agreement includes a comprehensive chemistry, manufacturing and controls (CMC) package suitable for the preparation of a Drug Master File (DMF), and provides exclusive access to [18F]AlF-PSMA-11 clinical safety and efficacy data, including a Phase 3 trial in 96 prostate cancer patients, where PSMA-11 (gozetotide) was labeled interchangeably with 18F and 68Ga.
The trial demonstrated diagnostic performance comparable to commercial 68Ga-labeled PSMA-11 agents such as Illuccix® and Gozellix®, both known to deliver high specificity (~90%) for metastatic detection at initial staging[5]. [18F]AlF-PSMA-11 has also demonstrated favorable biodistribution, high tumor-to-background ratios, and low off-target uptake in multiple studies[6]. Telix has commenced engagement with regulators to determine the pathway to approval for [18F]AlF-PSMA-11.
Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, “Telix’s goal is to expand the utilization of PSMA-PET imaging through clinical leadership and novel, flexible product deployment that enables physician choice. AlFluor™ is an example of innovation that meets the evolving needs of physicians and their patients. The addition of this advanced-stage technology and product candidate aligns with our strategy to offer the broadest choice of PSMA-PET imaging agents, with the service, flexibility and reliability that define the Telix customer experience.”
[1] Positron emission tomography.
[2] Prostate-specific membrane antigen.
[3] Neuroendocrine tumors.
[4] Fibroblast activation protein.
[5] PSMA-PreRP clinical study. ClinicalTrials.gov ID: NCT02919111.
[6] Piron et al. Sci Rep. 2021; Malik et al. EJNMMI Res. 2020; Boschi et al. EJNMMI Res. 2020.